Forte Biosciences Inc (FBRX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Forte Biosciences Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 76.60 $ — 99% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 3.7% below the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 4
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -3.83 | -4.48 – -3.22 | 0 | 18.6% | 5 |
| 12/31/2027 | -4.04 | -5.91 – -2.89 | 0 | -5.3% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -1.08 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.35 | – | 0 | 533.30 | -18,828.90 | -10 | -10 |
| 2025: Q1 | -0.76 | – | 0 | -100.00 | – | -10 | -10 |
| 2025: Q2 | -0.55 | – | 0 | – | – | -10 | -10 |
| 2025: Q3 | -0.86 | – | 0 | – | – | -14 | -14 |
| 2025: Q4 | -1.21 | – | 0 | -100.00 | – | -17 | -17 |
| 2026: Q1 | -1.08 | – | 0 | – | – | -19 | -19 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -32 | -33 | -634.80 | -30 | 7 | 35 |
| 2017 | 0 | -38 | -39 | -999.38 | -31 | 71 | 92 |
| 2018 | 18 | -46 | -49 | -36.61 | -34 | 58 | 103 |
| 2019 | 0 | -4 | -4 | -48.25 | -3 | 6 | 8 |
| 2020 | 0 | -14 | -46 | -157.93 | -18 | 59 | 61 |
| 2021 | 0 | -21 | -22 | -38.85 | -17 | 42 | 43 |
| 2022 | 0 | -14 | -14 | -19.94 | -8 | 39 | 42 |
| 2023 | 0 | -32 | -31 | -24.92 | -29 | 35 | 39 |
| 2024 | 0 | -37 | -35 | -12.17 | -31 | 52 | 62 |
| 2025 | 0 | -71 | -69 | -0.47 | -51 | 61 | 83 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Forte Biosciences, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase in den USA.
| Employees | 22 |
|---|---|
| Headquarters | Dallas, TX |
| Address | 3060 Pegasus Park Drive, 75247 Dallas, United States |
| Phone | 310 618 6994 |
| Website | fortebiorx.com |
| IPO Date | 13. Apr 2017 |
| ISIN | US34962G2084 |
| Stock Split | 1:25 on 08/28/2024 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Paul A. Wagner Ph.D. | CEO, President & Chairman | 1970 |
| Christopher Roenfeldt | Chief Operating Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.